

Magle Group Secures Registration of SmartPAN® in Singapore, Enabling Launch in Pancreatic Surgery

Magle Group today announced that its proprietary surgical innovation, SmartPAN®, has been successfully registered in Singapore. This achievement allows the company to initiate the commercial launch of SmartPAN® in one of Asia's leading healthcare markets.

SmartPAN® is a bioindicator specifically developed to support surgeons in pancreatic surgery. The product provides enhanced visualisation during surgery, helping surgeons to identify and assess potential leakage sites with greater confidence. By offering a clear intraoperative signal, SmartPAN® supports surgical decision-making in one of the most complex and challenging fields of surgery.

Registration in Singapore represents a significant step forward in Magle Group's global strategy for SmartPAN®, extending access to a technology that reflects the Group's commitment to patient-centric innovation.

"We are delighted that SmartPAN® has now been successfully registered in Singapore," said Helena Ossmer Thedius, Chief Marketing & Innovation Officer, Magle Group. "This milestone allows us to bring SmartPAN® to surgeons in a new market, where it can serve as a valuable bioindicator in pancreatic surgery and strengthen surgical confidence in the operating theatre."

The commercial launch in Singapore will be carried out together with local partners and surgical stakeholders, with the aim of establishing SmartPAN® as a trusted bioindicator in operating theatres.

Contacts Justin & Aaron

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

Aaron Wong, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmaceut.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

[Magle Group Secures Registration of SmartPAN® in Singapore, Enabling Launch in Pancreatic Surgery](#)